Please login to the form below
granulomatosis
This page shows the latest granulomatosis news and features for those working in and with pharma, biotech and healthcare.
Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis
Amgen’s treatment has already been approved for use in adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Latest news
-
Nucala works in rare inflammatory disease, says GSK
lungs. GSK is planning to file for approval of Nucala in HES next year, hoping to add to its currently-approved use in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
-
CHMP backs Sanofi’s all-oral sleeping sickness drug
remission with minimal residual disease greater than or equal to 0.1%, and also backed Roche’s MabThera (rituximab) for adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis in
-
Roche’s MabThera ends drug drought for serious skin disease
Rituximab already has a long list of approved indications – including autoimmune disease rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA) – and despite being on the market for more than
-
GSK gets another approval for Nucala in US
The US regulator gave the go-ahead yesterday to use Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, inflammation in
-
GSK preps COPD filing for asthma pioneer Nucala
with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder characterised by widespread inflammation in the walls of small blood vessels.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Exploring the potential of eosinophils
eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Red Thread Market Access Ltd
Blending brilliant writing with in-depth market access and reimbursement expertise...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
